Need a specific person's email?
Browse Eurofins DiscoverX's employee directory (about 120 employees) and reveal verified emails free.
Eurofins DiscoverX's most common email format is FLast@discoverx.com (ex. JDoe@discoverx.com), used for 77% of discoverx.com addresses. Eurofins DiscoverX uses 8 email patterns across 2 domains: discoverx.com and eurofins.com. Percentages are the share of addresses within each domain.
| Format | Example | Share of discoverx.com |
|---|---|---|
| FLast@discoverx.comMost common | JDoe@discoverx.com | |
| First.Last@discoverx.com | John.Doe@discoverx.com | |
| FirstL@discoverx.com | JohnD@discoverx.com | |
| Last_First@discoverx.com | Doe_John@discoverx.com |
| Format | Example | Share of eurofins.com |
|---|---|---|
| FirstLast@eurofins.comMost common | JohnDoe@eurofins.com | |
| FirLast@eurofins.com | JohDoe@eurofins.com | |
| FirstMiddleLast@eurofins.com | JohnMichaelDoe@eurofins.com | |
| FirstLas@eurofins.com | JohnDoe@eurofins.com |
Browse Eurofins DiscoverX's employee directory (about 120 employees) and reveal verified emails free.
Biotechnology ResearchCalifornia, United States51-200 Employees
Eurofins DiscoverX functions as the product arm of Eurofins Discovery, supplying tools that support multi-modality drug discovery and development from initial research through QC lot release. Its portfolio includes cell-based assays, ready-to-use kits, stable cell lines, and other assay components that enable work across a range of target families, such as cytokine and checkpoint receptors, GPCRs, kinases, ion channels, epigenetic regulators, and nuclear receptors. The company operates three research and manufacturing centers of excellence in Fremont, California; St. Charles, Missouri; and Poitiers, France. Its customers are drug discovery and development scientists in biotech and pharmaceutical organizations who rely on these tools to advance programs, including potency assessment, target engagement, and quality-control lot release. Based in Fremont, California, Eurofins DiscoverX operates within the biotechnology research industry as a supplier of research tools that enable multi-modality approaches. A recent 2023 update notes work on agonistic antibodies for immunotherapy and autoimmune diseases, reflecting ongoing expansion of its offerings in antibody-related assays.
Most common format
FLast@discoverx.com
Example: JDoe@discoverx.com
Free with a LeadIQ account. No credit card.
Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.